{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:08:27Z","timestamp":1780441707006,"version":"3.54.1"},"reference-count":11,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das Nierenzellkarzinom (NZK) macht etwa 13,5% aller urologischen Tumorerkrankungen aus. Die Versorgungsforschung (VF) analysiert, ob in kontrollierten Studien entwickelte und in medizinischen Leitlinien empfohlene Behandlungskonzepte unter Alltagsbedingungen auch umgesetzt werden. In diesem Beitrag soll die VF zum NZK anhand aktueller Daten aus der prospektiven VERSUS-Studie (VERSorgUngsStudie) von d-uo (Deutsche Uro-Onkologen) vorgestellt werden.<\/jats:p>\n                  <jats:p>Die VERSUS-Studie ist eine nicht-interventionelle, prospektive, multizentrische Studie zur Dokumentation und deskriptiven statistischen Auswertung von Diagnostik, Behandlungsverlauf und Nachsorge uro-onkologischer Patienten.<\/jats:p>\n                  <jats:p>Bei aktuell 31.419 in die VERSUS-Studie eingeschlossenen Patienten liegt bei 2526 ein NZK vor. In 22,7% erfolgte die Diagnose durch eine Symptomatik, in 38,1% durch eine Fr\u00fcherkennung. M\u00e4nner mit Symptomatik hatten in 38,3% der F\u00e4lle ein UICC-Stadium III oder IV gegen\u00fcber nur bei 24,8% der Frauen. Die Tumorstadien waren T1a in 35,6%, T1b in 21,5%, T2 in 7,2%, T3 in 11,1%, T4 N0 M0 in 0,2%, T1\u20134 N1\u20133 in 1,0% und T1\u20134 M1 in 3,6%. Die Nephrektomierate im Stadium T1 betrug 25,9%. Eine systemische Therapie erfolgte in 97 auswertbaren F\u00e4llen (13,1%), davon in 45,2% adjuvant und in 46,4% bei vorliegender Metastasierung.<\/jats:p>\n                  <jats:p>Trotz aktueller und interessanter Daten ist die VERSUS-Studie, die auf dem gleichen Basisdatensatz wie die Krebsregistermeldung basiert, aufgrund der begrenzten Datentiefe limitiert. Um die VF umfassend und mit der notwendigen Datentiefe analysieren zu k\u00f6nnen, sind organbezogene Register wie das Nationale Register Urothelkarzinom (UroNAT) und das Nationale Register Prostatakarzinom (ProNAT) von d-uo erforderlich. Diese Register sind einzigartig, da sie bei d-uo alle Tumorstadien umfassen. Das Nationale Register NZK (ReNAT) von d-uo ist in Vorbereitung und wird einen weiteren wertvollen Beitrag zur Qualit\u00e4tssicherung der onkologischen Versorgung in Deutschland leisten.<\/jats:p>","DOI":"10.1055\/a-2787-4541","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:06:28Z","timestamp":1771286788000},"page":"270-274","source":"Crossref","is-referenced-by-count":0,"title":["Versorgungsforschung zum Nierenzellkarzinom: 7-Jahres-Daten aus der VERSUS-Studie von d-uo"],"prefix":"10.1055","volume":"57","author":[{"given":"Manfred","family":"Johannsen","sequence":"additional","affiliation":[{"name":"Facharztpraxis Urologie, Germany","place":["Berlin"],"department":["Urologie"]},{"name":"Vorstand d-uo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Eichenauer","sequence":"additional","affiliation":[{"name":"Vorstand d-uo"},{"name":"Urologikum MVZ, Germany","place":["Hamburg"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Klier","sequence":"additional","affiliation":[{"name":"Vorstand d-uo"},{"name":"UPK K\u00f6ln, Germany","place":["K\u00f6ln"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Vorstand d-uo"},{"name":"ATURO Berlin, Germany","place":["Berlin"],"department":["Urology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sch\u00f6nfelder","sequence":"additional","affiliation":[{"name":"Vorstand d-uo"},{"name":"Dres. Sch\u00f6nfelder & Stra\u00dfer, Germany","place":["Hamburg"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"Vorstand d-uo"},{"name":"ATURO Berlin, Germany","place":["Berlin"],"department":["Urology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hempel","sequence":"additional","affiliation":[{"name":"SMGF Forschungsgesellschaft, Germany","place":["Berlin"],"department":["d-uo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Doehn","sequence":"additional","affiliation":[{"name":"Vorstand d-uo"},{"name":"UKSH Campus L\u00fcbeck, Germany","place":["L\u00fcbeck"],"department":["Urologikum L\u00fcbeck und Klinik f\u00fcr Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"ref2","first-page":"74","article-title":"6 Jahre VERSUS-Studie von d-uo","volume":"10","author":"C Doehn","year":"2024","journal-title":"Journal Onkologie"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/a-2065-8957","article-title":"Die Krebsregistermeldung aus der Sicht der Deutschen Uro-Onkologen (d-uo)","volume":"54","author":"C Doehn","year":"2023","journal-title":"Aktuelle Urol"},{"key":"ref4","first-page":"66","article-title":"Neudiagnose Nierenzellkarzinom: Ergebnisse aus der nicht-interventionellen, prospektiven VERSUS-Studie von d-uo","volume":"3","author":"C Doehn","year":"2022","journal-title":"Journal Onkologie"},{"key":"ref5","first-page":"20","article-title":"Adjuvante Therapie des Nierenzellkarzinoms \u2013 eine Fallzahlabsch\u00e4tzung von d-uo","volume":"1","author":"C Doehn","year":"2023","journal-title":"UroForum"},{"key":"ref6","first-page":"58","article-title":"Das symptomatische Nierenzellkarzinom: Ergebnisse aus der VERSUS-Studie von d-uo","volume":"2","author":"C Doehn","year":"2024","journal-title":"Journal Onkologie"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s00120-024-02465-6","article-title":"Neues von d-uo: Was kann die Versorgungsforschung beim Nierenzellkarzinom leisten?","volume":"63","author":"M Johannsen","year":"2024","journal-title":"Die Urologie"},{"key":"ref8","first-page":"66","article-title":"Symptomatisches Nierenzellkarzinom: Neues aus der VERSUS-Studie von d-uo","volume":"4","author":"M Johannsen","year":"2025","journal-title":"Journal Onkologie"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00120-011-2583-x","article-title":"Die Urologie braucht Versorgungsforschung: Argumente am Beispiel der operativen Therapie kleiner Nierentumore","volume":"50","author":"F Hoffmann","year":"2011","journal-title":"Der Urologe"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/a-2041-3063","article-title":"Krebsregister in Deutschland: Was bringt die Zukunft f\u00fcr die Urologie?","volume":"54","author":"K Kraywinkel","year":"2023","journal-title":"Aktuelle Urol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"29163","DOI":"10.1038\/s41598-025-14493-z","article-title":"Prognostic comparison of partial and radical nephrectomy for T1b renal cell carcinoma with SEER database analysis","volume":"15","author":"H Liu","year":"2025","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/a-2065-8990","article-title":"Nationale Register Urothelkarzinom (UroNAT) und Prostatakarzinom (ProNAT) von d-uo","volume":"54","author":"M Johannsen","year":"2023","journal-title":"Akt Urol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2787-4541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:33:23Z","timestamp":1780439603000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2787-4541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":11,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,6,2]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2787-4541","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}